1227637-23-1CC1CC(C)CN(S(=O)(=O)c2ccc3c(NO)c4ccc(S(=O)(=O)N5CC(C)CC(C)C5)cc4c(N=O)c3c2)C1OMWCXCBGEFHCTN-UHFFFAOYSA-NTegavivint is a small molecule inhibitor of the Wnt/beta-catenin pathway with potential antineoplastic activity. Upon intravenous administration, tegavivint binds to transducin beta-like protein 1 (TBL1) and disrupts the binding of beta-catenin to TBL1. This promotes beta-catenin degradation, attenuates nuclear and cytoplasmic levels of beta-catenin, and reduces transcriptional activity of transcription factor 4 (TCF4) and expression of its target genes, cyclin D1, c-Myc and survivin. The Wnt/beta-catenin signaling pathway regulates cell morphology, motility, and proliferation; aberrant regulation of this pathway leads to neoplastic proliferation. Beta-catenin is frequently mutated in various tumors.
1227637-23-1CHEMBL3601411安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
現在のフィルター条件では反応記録がありません。
読み込み中…